Harvey's Garden

Diabetic gastroparesis

Properties2
tags—
aliases

2 min read

Diabetic gastroparesis is a complication of long-term diabetes characterized by delayed gastric emptying that is not associated with mechanical obstruction.

Epidemiology

Etiology

Pathophysiology

  • Poor glycemic control, sustained hyperglycemia > 200 mg/dL → neuronal damage → impaired neural control of gastric function (e.g., interstitial cells of Cajal dysfunction, abnormal myenteric neurotransmission, smooth muscle dysfunction, vagal dysfunction) → antral motor coordination and function abnormalities (↓ antral contractions, pyloric spasms, abnormal antroduodenal contractions) → delayed gastric emptying

Clinical features

  • Early satiety and postprandial fullness.
  • Nausea and vomiting of undigested food consumed hours prior. c
  • Bloating and upper abdominal discomfort.
  • Weight loss and malnutrition in severe cases.
  • Erratic glycemic control (difficulty matching preprandial insulin dosing to delayed nutrient absorption, leading to postprandial hypoglycemia).
  • Physical Exam: Succussion splash heard over the epigastrium >3 hours after a meal (indicates retained gastric contents).
  • Complications
    • Bezoars: Solid mass of indigestible material accumulating in the stomach. t

Diagnostics

  • Initial Step: Esophagogastroduodenoscopy (EGD) or barium swallow.
    • Done to rule out mechanical gastric outlet obstruction (e.g., peptic ulcer disease, malignancy) or active mucosal disease.
    • Retention of food in the stomach after an overnight fast is highly suggestive.
  • Confirmatory/Gold Standard: 4-hour Scintigraphic Gastric Emptying Study (solid phase). c
    • Diagnostic threshold: >10% retention at 4 hours (or >60% retention at 2 hours).
  • Key Labs:
    • Elevated HbA1c (indicates chronic poor control).
    • Basic metabolic panel (BMP) to assess for hypokalemia, hypochloremia, and metabolic alkalosis from persistent vomiting.

Treatment

  1. Dietary and Lifestyle Modifications (First-line):
    • Small, frequent meals (5–6 small meals/day).
    • Low-fat, low-fiber diet (fat slows emptying; fiber increases bezoar risk).
    • Liquid-phase nutrients are emptied faster than solids.
    • Avoid tobacco, alcohol, and carbonated beverages.
    • Optimize glycemic control (target HbA1c < 7% to decrease neuropathy progression).
  2. Prokinetic Therapy (First-line Pharmacotherapy):
    • Metoclopramide (D2 receptor antagonist and 5-HT4 agonist).
      • Taken 15–30 mins before meals and at bedtime.
      • Risk of tardive dyskinesia (black box warning limit use to <12 weeks) and extrapyramidal symptoms (EPS).
    • Erythromycin (Motilin receptor agonist).
      • Used mainly for acute flares (IV/PO) or short-term therapy.
      • High risk of tachyphylaxis (rapid tolerance) and QT prolongation.
  3. Antiemetic Therapy (Symptom Control):
    • Ondansetron (5-HT3 antagonist), promethazine, or prochlorperazine.
  4. Refractory Cases:
    • Gastric electrical stimulation (Enterra device).
    • Endoscopic pyloromyotomy (G-POEM) or surgical feeding jejunostomy (bypass stomach for nutrition).

Graph View

Backlinks